IRCT20200105046010N96 IRCT 2024-02-17 شرکت فاران فارمد Bioequivalence study of Empagliflozin/Linagliptin 25/5 mg Bioequivalence study of Empagliflozin/Linagliptin 25/5 mg manufactured by faran pharmed Co.versus originator brand GLYXAMBI® 25/5 mg manufactured by ‌‌Boehringer ‌‌‌‌‌ Co in fasting condition in healthy volunteers 2024-02-11 anticipated 24 Complete https://irct.ir/trial/75421 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Crossover, Purpose: Treatment, Randomization description: People in the mentioned age group are invited to participate through the advertisement. People are then checked for health and healthy volunteers are identified. Each candidate is assigned a number from 1 to 24. The numbers are written on a plastic ball and poured into a container and mixed. The balls are then removed randomly from the container. The first 12 no.s are considered as (first sequence: Faran pharmed's medicine ) and the second 12 no.s are considered as (second sequence: originator brand recipient). The volunteers don't have any information about taking the test drug or brand drug, Blinding description: This study is a single-blinded clinical trial (volunteers). Test and Originator brand's tablets are removed from their packaging by the executor and placed in similar and coded cans. Volunteers will not be informed about receiving the brand or test dosage form. Bioequivalence This study is performed on healthy volunteers and drug concentration in plasma is determined.. Intervention 1: Intervention group: single dose, one oral GLYXAMBI® 25/5 mg manufactured by ‌‌Boehringer ‌‌‌‌‌ Co as a reference product. after the washout period, the volunteers receive JARLINO Tab. 25/5 mg ) tablet Faran pharmed Co. Intervention 2: Intervention group: Single dose, JARLINO Tab. 25/5 mg ) tablet Faran pharmed Co. as a test product. after the washout, the volunteers receive GLYXAMBI® 25/5 mg manufactured by ‌‌Boehringer ‌‌‌‌‌Pharmaceuticals. No - There is not a plan to make this available Justification or reason for not sharing IPD is These data are as secure between researchers and related industries.